Ypsomed Holding AG (CH:YPSN)
:YPSN
Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF307.50
-CHF5.00(-1.41%)
At close: 4:00 PM EST
CHF307.50
-CHF5.00(-1.41%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF441.50
Previous CloseN/A
Volume2.70K
Average Volume (3M)17.31K
Market Cap
CHF3.84B
Enterprise ValueCHF3.89B
Total Cash (Recent Filing)CHF36.30M
Total Debt (Recent Filing)CHF110.00M
Price to Earnings (P/E)7.7
Beta0.54
Next Earnings
May 27, 2026Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)10.19
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)6.82
Price to Sales (P/S)6.19
P/FCF Ratio-35.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF343.00Price Target Upside11.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)13.29
Revenue Forecast (FY)CHF703.86M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 36.5% YoY revenue lift to CHF 748.9m demonstrates durable demand for Ypsomed's device and diabetes offerings. Sustained top-line growth supports operating leverage, funds continued R&D and capacity buildouts, and strengthens negotiating power with pharma partners over the medium term.
High Delivery Systems MarginsA 32.4% EBIT margin in Delivery Systems signals robust unit economics from proprietary designs, scale manufacturing and partner contracts. High, sustainable margins enhance cash generation potential and provide a durable buffer against price pressure and costs, supporting reinvestment capacity.
Conservative Capital StructureModerate leverage and an equity-heavy balance sheet give Ypsomed financial flexibility to fund expansion. A D/E of 0.39 and solid equity ratio reduce refinancing risk, enabling the company to pursue multi-year CapEx and strategic investments without compromising solvency over the next several quarters.
Bears Say
Negative Free Cash FlowSustained negative FCF of CHF -128.9m from heavy CapEx weakens internal funding capacity. Over a 2-6 month horizon this elevates reliance on external financing or customer co-investments, and constrains flexibility for dividends, opportunistic M&A or cushioning operational shortfalls if investments delay revenue realization.
Weakness In Diabetes & Pen SegmentsFlat pen sales and a CHF 5m loss in Diabetes Care indicate commercialization and mix challenges in end-market products. This undermines recurring consumables revenue and diversification, leaving overall performance more reliant on large drug-delivery contracts and increasing exposure if those contracts slow.
Large CapEx & Execution RiskA CHF 1.5bn multi-year CapEx program to triple capacity creates material execution and demand risk. If partner demand or co-investments fall short, payback periods lengthen, cash conversion worsens and returns may be muted. Successful facility rollout across jurisdictions is required to realize scale benefits.
Ypsomed Holding AG News
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF441.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF3.84B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is May 27, 2026 which is in 29 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on Nov 12, 2025. The company reported CHF10.19 earnings per share for the quarter, beating the consensus estimate of CHF9.11 by CHF1.08.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF2.2 which represents an annual dividend yield of 0.67%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 6.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF10.19 in its last earnings report, beating expectations of CHF9.11. Following the earnings report the stock price went up 4.938%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF343.00
▲(11.54% Upside)
Technical Analysis
Options Prices
Currently, No data available
---